Colonial Trust Advisors’s BridgeBio Pharma BBIO Stock Holding History

Colonial Trust Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-22	Closed	-$604	–	677
2024 Q4	$604	Hold	22	–	–	﹤0.01%	645
2024 Q3	$560	Hold	22	–	–	﹤0.01%	720
2024 Q2	$557	Hold	22	–	–	﹤0.01%	716
2024 Q1	$680	Buy	+22	New	+$748	﹤0.01%	890

Other funds holding BBIO

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Colonial Trust Advisors's BBIO Position: Q1 2025 in Review

Colonial Trust Advisors sold out of BridgeBio Pharma (BBIO) in Q1 2025, closing a stake of 22 shares — an estimated $604 sold.

Colonial Trust Advisors first reported a position in BBIO in Q1 2024 and held it in 4 quarters. The position peaked at $680 in Q1 2024. 304 funds tracked by Wall St. Rank hold BBIO as of Q1 2025.

Colonial Trust Advisors reported no remaining BridgeBio Pharma position as of Q1 2025 after selling out during the quarter.
Colonial Trust Advisors sold 22 BridgeBio Pharma shares in Q1 2025, an estimated $604.
Colonial Trust Advisors first reported a position in BridgeBio Pharma in Q1 2024 and held it in 4 quarters.
Colonial Trust Advisors's BridgeBio Pharma position peaked at $680 in Q1 2024.
304 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2025.

Based on Colonial Trust Advisors's 13F filing for Q1 2025, filed 14 May 2025.